Vaccinex, Inc. (VCNX): IPOs News

VCNX – Prices 3.33 mln share IPO at $12.00, the low-end of the expected $12.00-15.00 range.

Key Facts Surrounding This News Item

  • VCNX had returned 0.00% year-to-date leading up to today’s news, versus a +7.88% return from the benchmark S&P 500 during the same period.

More Info About Vaccinex, Inc. (VCNX)

Vaccinex, Inc. operates as a clinical-stage biotechnology company. It engages in the discovery and development of bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is VX15 that is in Phase Ib/II clinical trials for the treatment of advanced solid tumors, including non-small cell lung cancer, osteosarcoma, and melanoma; and Phase II clinical trials for the treatment of Huntington’s disease. The company’s preclinical development products include VX5, a human antibody to CXCL13, a molecule that regulates the formation of immune tissues, for the treatment of MS and other autoimmune disorders; and VX25 is an investigational and bi-specific molecule for the therapeutic application of Natural Killer T cell stimulation for cancer immunotherapy. Vaccinex, Inc. was founded in 2001 and is based in Rochester, New York. View our full VCNX ticker page with ratings, news, and more.

VCNX at a Glance

VCNX Current POWR Rating™
Overall POWR Rating™
VCNX Current Price $4.93 10.36%
More VCNX Ratings, Data, and News

VCNX Price Reaction

The day of this event (Aug. 9, 2018)
VCNX Closing Price$11.38 N/A%
VCNX Volume688,400
N/A% from avg
Leading up to this event
VCNX 1-mo returnN/A%
After this event
VCNX 1-day returnN/A%
VCNX 3-day returnN/A%
VCNX 5-day returnN/A%

VCNX Price Chart

The Top Stocks For 2019

More Vaccinex, Inc. (VCNX) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All VCNX News
Page generated in 0.7406 seconds.